Annual EBIT
-$8.13 M
+$244.40 K+2.92%
June 30, 2024
Summary
- As of February 7, 2025, INM annual earnings before interest & taxes is -$8.13 million, with the most recent change of +$244.40 thousand (+2.92%) on June 30, 2024.
- During the last 3 years, INM annual EBIT has risen by +$1.71 million (+17.36%).
- INM annual EBIT is now -17318.42% below its all-time high of -$46.70 thousand, reached on June 30, 2013.
Performance
INM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$1.75 M
+$254.70 K+12.68%
September 30, 2024
Summary
- As of February 7, 2025, INM quarterly earnings before interest & taxes is -$1.75 million, with the most recent change of +$254.70 thousand (+12.68%) on September 30, 2024.
- Over the past year, INM quarterly EBIT has increased by +$41.90 thousand (+2.33%).
- INM quarterly EBIT is now -120.55% below its all-time high of $8.54 million, reached on June 30, 2007.
Performance
INM Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$7.26 M
+$870.10 K+10.70%
September 30, 2024
Summary
- As of February 7, 2025, INM TTM earnings before interest & taxes is -$7.26 million, with the most recent change of +$870.10 thousand (+10.70%) on September 30, 2024.
- Over the past year, INM TTM EBIT has dropped by -$622.60 thousand (-9.37%).
- INM TTM EBIT is now -195.06% below its all-time high of $7.64 million, reached on March 31, 2008.
Performance
INM TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
INM EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.9% | +2.3% | -9.4% |
| 3 y3 years | +17.4% | +42.4% | +47.3% |
| 5 y5 years | +19.4% | +6.8% | -2.5% |
INM EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +41.0% | -239.8% | +59.3% | -9.4% | +49.5% |
| 5 y | 5-year | at high | +41.0% | -239.8% | +59.3% | -9.4% | +49.5% |
| alltime | all time | <-9999.0% | +41.0% | -120.5% | +59.3% | -195.1% | +49.5% |
InMed Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.75 M(-12.7%) | -$7.26 M(-10.7%) |
| Jun 2024 | -$8.13 M(-2.9%) | -$2.01 M(+11.8%) | -$8.13 M(+22.5%) |
| Mar 2024 | - | -$1.80 M(+5.4%) | -$6.64 M(-5.0%) |
| Dec 2023 | - | -$1.70 M(-35.0%) | -$6.99 M(-7.0%) |
| Sep 2023 | - | -$2.62 M(+408.3%) | -$7.52 M(-10.2%) |
| Jun 2023 | -$8.38 M(-39.2%) | -$516.30 K(-76.0%) | -$8.38 M(-23.2%) |
| Mar 2023 | - | -$2.15 M(-3.8%) | -$10.91 M(-11.3%) |
| Dec 2022 | - | -$2.23 M(-35.8%) | -$12.30 M(-14.5%) |
| Sep 2022 | - | -$3.48 M(+14.2%) | -$14.38 M(+4.3%) |
| Jun 2022 | -$13.79 M(+40.1%) | -$3.05 M(-13.9%) | -$13.79 M(-1.5%) |
| Mar 2022 | - | -$3.54 M(-17.9%) | -$14.00 M(+3.2%) |
| Dec 2021 | - | -$4.31 M(+49.1%) | -$13.57 M(+21.8%) |
| Sep 2021 | - | -$2.89 M(-11.2%) | -$11.14 M(+13.5%) |
| Jun 2021 | -$9.84 M(+10.1%) | -$3.26 M(+5.1%) | -$9.81 M(+20.1%) |
| Mar 2021 | - | -$3.10 M(+64.7%) | -$8.17 M(+15.2%) |
| Dec 2020 | - | -$1.88 M(+20.4%) | -$7.09 M(-7.9%) |
| Sep 2020 | - | -$1.56 M(-3.2%) | -$7.70 M(-14.6%) |
| Jun 2020 | -$8.94 M(-11.5%) | -$1.62 M(-20.1%) | -$9.01 M(-14.1%) |
| Mar 2020 | - | -$2.02 M(-18.8%) | -$10.50 M(-5.6%) |
| Dec 2019 | - | -$2.49 M(-13.4%) | -$11.11 M(+3.2%) |
| Sep 2019 | - | -$2.88 M(-7.0%) | -$10.77 M(+6.3%) |
| Jun 2019 | -$10.10 M(+54.2%) | -$3.10 M(+17.3%) | -$10.13 M(+8.9%) |
| Mar 2019 | - | -$2.64 M(+23.1%) | -$9.30 M(+11.6%) |
| Dec 2018 | - | -$2.15 M(-4.2%) | -$8.33 M(+12.4%) |
| Sep 2018 | - | -$2.24 M(-1.3%) | -$7.41 M(+11.7%) |
| Jun 2018 | -$6.55 M(+90.3%) | -$2.27 M(+35.9%) | -$6.64 M(+13.3%) |
| Mar 2018 | - | -$1.67 M(+35.9%) | -$5.85 M(+14.5%) |
| Dec 2017 | - | -$1.23 M(-16.0%) | -$5.11 M(+11.6%) |
| Sep 2017 | - | -$1.46 M(-1.8%) | -$4.58 M(+33.3%) |
| Jun 2017 | -$3.44 M(+87.2%) | -$1.49 M(+60.3%) | -$3.44 M(+46.7%) |
| Mar 2017 | - | -$929.40 K(+32.9%) | -$2.34 M(+37.2%) |
| Dec 2016 | - | -$699.40 K(+118.7%) | -$1.71 M(+9.0%) |
| Sep 2016 | - | -$319.80 K(-19.3%) | -$1.57 M(-11.1%) |
| Jun 2016 | -$1.84 M(-46.8%) | -$396.10 K(+35.0%) | -$1.76 M(-31.7%) |
| Mar 2016 | - | -$293.40 K(-47.4%) | -$2.58 M(-27.6%) |
| Dec 2015 | - | -$558.30 K(+8.1%) | -$3.57 M(+2.0%) |
| Sep 2015 | - | -$516.50 K(-57.5%) | -$3.50 M(-1.9%) |
| Jun 2015 | -$3.46 M(+200.2%) | -$1.21 M(-5.0%) | -$3.57 M(+5.9%) |
| Mar 2015 | - | -$1.28 M(+161.1%) | -$3.37 M(+54.4%) |
| Dec 2014 | - | -$489.70 K(-16.2%) | -$2.18 M(+26.3%) |
| Sep 2014 | - | -$584.50 K(-42.4%) | -$1.73 M(+49.7%) |
| Jun 2014 | -$1.15 M(+2365.3%) | -$1.01 M(+999.5%) | -$1.15 M(+615.0%) |
| Mar 2014 | - | -$92.30 K(+162.2%) | -$161.30 K(+110.6%) |
| Dec 2013 | - | -$35.20 K(+220.0%) | -$76.60 K(+116.4%) |
| Sep 2013 | - | -$11.00 K(-51.8%) | -$35.40 K(-25.2%) |
| Jun 2013 | -$46.70 K | -$22.80 K(+200.0%) | -$47.30 K(-53.2%) |
| Mar 2013 | - | -$7600.00(-226.7%) | -$101.10 K(-13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | - | $6000.00(-126.2%) | -$116.20 K(-21.8%) |
| Sep 2012 | - | -$22.90 K(-70.1%) | -$148.50 K(-10.8%) |
| Jun 2012 | -$168.60 K(-46.3%) | -$76.60 K(+237.4%) | -$166.40 K(+73.0%) |
| Mar 2012 | - | -$22.70 K(-13.7%) | -$96.20 K(-67.2%) |
| Dec 2011 | - | -$26.30 K(-35.5%) | -$293.10 K(-2.9%) |
| Sep 2011 | - | -$40.80 K(+537.5%) | -$302.00 K(-2.5%) |
| Jun 2011 | -$313.80 K(-23.7%) | -$6400.00(-97.1%) | -$309.80 K(-31.8%) |
| Mar 2011 | - | -$219.60 K(+523.9%) | -$454.30 K(+40.9%) |
| Dec 2010 | - | -$35.20 K(-27.6%) | -$322.50 K(-14.0%) |
| Sep 2010 | - | -$48.60 K(-67.8%) | -$374.90 K(-7.5%) |
| Jun 2010 | -$411.40 K(-47.1%) | -$150.90 K(+71.9%) | -$405.10 K(+14.7%) |
| Mar 2010 | - | -$87.80 K(+0.2%) | -$353.30 K(-1.3%) |
| Dec 2009 | - | -$87.60 K(+11.2%) | -$358.10 K(-32.0%) |
| Sep 2009 | - | -$78.80 K(-20.5%) | -$527.00 K(-37.6%) |
| Jun 2009 | -$777.00 K(-38.8%) | -$99.10 K(+7.0%) | -$844.70 K(-36.9%) |
| Mar 2009 | - | -$92.60 K(-63.9%) | -$1.34 M(-4.2%) |
| Dec 2008 | - | -$256.50 K(-35.3%) | -$1.40 M(-5.3%) |
| Sep 2008 | - | -$396.50 K(-33.2%) | -$1.48 M(-0.9%) |
| Jun 2008 | -$1.27 M(+11.1%) | -$593.50 K(+294.1%) | -$1.49 M(-119.5%) |
| Mar 2008 | - | -$150.60 K(-55.1%) | $7.64 M(+1.0%) |
| Dec 2007 | - | -$335.40 K(-18.1%) | $7.57 M(+3.3%) |
| Sep 2007 | - | -$409.30 K(-104.8%) | $7.33 M(-1.8%) |
| Jun 2007 | -$1.14 M(-2.8%) | $8.54 M(-3933.5%) | $7.46 M(-635.5%) |
| Mar 2007 | - | -$222.70 K(-61.5%) | -$1.39 M(-13.0%) |
| Dec 2006 | - | -$577.90 K(+109.3%) | -$1.60 M(+22.0%) |
| Sep 2006 | - | -$276.10 K(-12.8%) | -$1.31 M(-4.8%) |
| Jun 2006 | -$1.18 M(-40.9%) | -$316.60 K(-26.6%) | -$1.38 M(-13.8%) |
| Mar 2006 | - | -$431.10 K(+49.2%) | -$1.60 M(+7.3%) |
| Dec 2005 | - | -$288.90 K(-15.6%) | -$1.49 M(-7.2%) |
| Sep 2005 | - | -$342.10 K(-36.2%) | -$1.61 M(-18.9%) |
| Jun 2005 | -$1.99 M(+60.1%) | -$536.40 K(+66.1%) | -$1.98 M(+4.0%) |
| Mar 2005 | - | -$322.90 K(-20.0%) | -$1.90 M(+3.4%) |
| Dec 2004 | - | -$403.70 K(-43.6%) | -$1.84 M(+5.3%) |
| Sep 2004 | - | -$715.20 K(+55.1%) | -$1.75 M(+38.5%) |
| Jul 2004 | -$1.24 M(-3.0%) | -$461.20 K(+77.3%) | -$1.26 M(+3.2%) |
| Apr 2004 | - | -$260.10 K(-16.4%) | -$1.22 M(+3.0%) |
| Jan 2004 | - | -$311.10 K(+35.4%) | -$1.19 M(+3.2%) |
| Oct 2003 | - | -$229.70 K(-45.6%) | -$1.15 M(-6.9%) |
| Jul 2003 | -$1.28 M(-53.5%) | -$422.30 K(+88.1%) | -$1.24 M(-10.3%) |
| Apr 2003 | - | -$224.50 K(-18.2%) | -$1.38 M(-25.0%) |
| Jan 2003 | - | -$274.60 K(-12.8%) | -$1.84 M(-19.8%) |
| Oct 2002 | - | -$314.80 K(-44.2%) | -$2.29 M(-16.2%) |
| Jul 2002 | -$2.75 M(-35.3%) | -$564.40 K(-17.5%) | -$2.74 M(+26.0%) |
| Apr 2002 | - | -$684.10 K(-6.2%) | -$2.17 M(+46.0%) |
| Jan 2002 | - | -$729.50 K(-3.7%) | -$1.49 M(+96.3%) |
| Oct 2001 | - | -$757.30 K | -$757.30 K |
| Jul 2001 | -$4.25 M | - | - |
FAQ
- What is InMed Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals annual EBIT year-on-year change?
- What is InMed Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals quarterly EBIT year-on-year change?
- What is InMed Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals TTM EBIT year-on-year change?
What is InMed Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of INM is -$8.13 M
What is the all time high annual EBIT for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high annual earnings before interest & taxes is -$46.70 K
What is InMed Pharmaceuticals annual EBIT year-on-year change?
Over the past year, INM annual earnings before interest & taxes has changed by +$244.40 K (+2.92%)
What is InMed Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of INM is -$1.75 M
What is the all time high quarterly EBIT for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high quarterly earnings before interest & taxes is $8.54 M
What is InMed Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, INM quarterly earnings before interest & taxes has changed by +$41.90 K (+2.33%)
What is InMed Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of INM is -$7.26 M
What is the all time high TTM EBIT for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high TTM earnings before interest & taxes is $7.64 M
What is InMed Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, INM TTM earnings before interest & taxes has changed by -$622.60 K (-9.37%)